Head-to-head · Value Score
Found vs Direct Meds
Two GLP-1 deals, scored on the same six factors. Found lands a Value Score of 90, Direct Meds a 82. Here's who gives you the honest lower price — and where each one bites back.
Found
#4 · Grade A · Best Value
Est. first month
$129/mo
Save ~90% vs brand-nameDirect Meds
#23 · Grade B+ · Good Value
Est. first month
$179/mo
Save ~87% vs brand-nameThe verdict
Found takes it on Value Score, 90 to 82 — an est. $129/mo first month, though we flag its pricing to watch. Direct Meds isn't out of it: Needle-averse shoppers who want a sublingual option on both molecules and will do their own diligence on a newer, ambiguous operator.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Found | Direct Meds |
|---|---|---|
| Value Score | 90 (A) | 82 (B+) |
| Est. first month | $129/mo | $179/mo |
| Save vs brand-name | ~90% | ~87% |
| Semaglutide | $129/mo | $179/mo |
| Tirzepatide | $129/mo | $224/mo |
| Both molecules | Yes | Yes |
| Pricing | Watch | Watch |
| Coverage | All 50 states | Not publicly listed |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Found
On sticker price alone, the cheapest deal here — identical $129 on both molecules, bundled into a coaching subscription.
Why it's a deal
- Cheapest disclosed price — identical $129 on both molecules
- Available in all 50 states
- Strong behavior-change coaching included
The fine print
- Price is tied to a coaching subscription you can't fully unbundle — factor the lock-in
- Compounded only
Direct Meds
One of the few programs offering an oral/sublingual GLP-1 alongside injectable, all-inclusive with no separate membership — priced well, but on company-stated numbers we couldn't independently verify.
Why it's a deal
- Rare oral/sublingual route offered alongside injectable on both molecules
- All-inclusive pricing with no separate membership fee
- Both semaglutide and tirzepatide available, sublingual or injectable
The fine print
- Compounded only (launched 2024) — not FDA-approved
- Prices are company-stated and could not be verified live; a promo rate blurs the ongoing price
- Newer, ambiguous operator running multiple domains — do your own diligence
- States served are not publicly listed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.